查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808609

數位生物標記市場按成分、生物標記類型、功能、治療領域、應用和最終用戶分類——2025-2030 年全球預測

Digital Biomarkers Market by Component, Biomarker Type, Functionality, Therapeutic Area, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年數位生物標記市場價值將達到 21.3 億美元，2025 年將成長至 23.6 億美元，到 2030 年將達到 39.6 億美元，複合年成長率為 10.80%。

主要市場統計數據
基準年2024年 21.3億美元
預計2025年 23.6億美元
預測年份 2030 39.6億美元
複合年成長率（%） 10.80%

引領數位生物標記成為個人化醫療和臨床洞察創新的變革力量

隨著數位生物標記物重新定義病患監測、診斷和治療發展的格局，醫療保健產業正在經歷一場根本性的變革。透過先進的感測器、穿戴式裝置和植入式裝置捕捉生理和行為數據，這些新指標使臨床醫生能夠持續評估健康狀況，而非僅進行單一評估。從依賴間歇性實驗室測量和成像的傳統生物標記物向數位生物標記物的演變，代表著疾病檢測、追蹤和治療方式的範式轉移。

開啟下一波創新浪潮：技術進步與監管突破塑造數位生物標記的未來

由於技術突破、監管環境的演變以及患者期望的變化，數位生物標記領域正在發生重大變化。感測器小型化和功率效率的突破性改進擴大了可在臨床環境之外捕獲的生理訊號範圍。穿戴式裝置即時數據收集能夠持續監測生命徵象、活動模式和睡眠指標，為早期療育和更精準的治療方法創造了機會。

評估 2025 年美國關稅政策對數位生物標記開發中供應鏈彈性和組件籌資策略的連鎖反應

美國新關稅的實施，為數位生物標記設備及組件的開發商和製造商帶來了挑戰和機會。進口感測器、微電子產品和先進材料面臨關稅上調，迫使他們調整籌資策略和供應鏈配置。為此，企業正在探索替代採購途徑，並實現供應商組合多元化，以緩解成本壓力。

透過多方面的組成部分、功能和治療重點來剖析數位生物標記生態系統

透過多角度檢驗數位生物標記物生態系統，我們發現了六個關鍵的細分標準，每個標準都提供了對市場動態和技術發展軌蹟的細緻洞察。組件分析揭示了硬體和軟體的二分法，硬體進一步分為植入、感測器和穿戴式設備，後者又細分為健身手環和智慧型手錶。這種差異凸顯了感測器外形規格如何影響健身保真度和使用者採用率：小型智慧型手錶裝置非常適合持續的生理監測，而消費性穿戴裝置則優先考慮易用性和參與度。

繪製區域採用差異圖，凸顯全球數位生物標記市場的監管協調與創新叢集

反映多樣化法律規範、醫療基礎設施和投資格局的區域動態將在塑造數位生物標記物的採用和成熟度方面發揮關鍵作用。在美洲，北美創新中心憑藉科技公司與醫療服務提供者之間的緊密夥伴關係引領潮流，而拉丁美洲市場正在探索試驗計畫，以將遠端監控能力擴展到資源匱乏的地區。該地區正在強調以患者為中心的價值提案，加速報銷對話，並塑造新的醫療服務模式。

介紹透過策略合作和技術融合推進數位生物標記整合的主要企業

主要企業正在製定策略路徑，以保持其領先地位，並加速將數位生物標記物整合到主流醫療保健領域。科技巨頭們正在透過收購專注於感測器的新興企業以及與數據分析公司合作來擴展其設備組合，以增強人工智慧能力。現有的醫療設備公司正在將數位終端整合到現有平台中，從而提高臨床試驗數據的粒度，並實現遠端患者參與。

透過互通性、病人參與和供應鏈彈性保持競爭優勢的策略要點

產業領導者必須採取多管齊下的策略，充分利用數位生物標記機會，並駕馭日益複雜的生態系統。投資符合新興資料交換標準的互通平台，將簡化與電子健康記錄和分析工具的整合，從而加快洞察獲取速度。與監管機構合作，優先考慮嚴格的驗證框架，將確保數位終端符合臨床試驗和報銷要求，從而促進更廣泛的認可。

透過初步訪談、文獻分析和數據三角測量相結合的方式，獲得全面的數位生物標記洞察

本分析綜合了嚴謹的混合方法研究途徑的成果。主要研究涉及對 50 多位相關人員的深入訪談，包括設備製造商、軟體開發商、醫療保健提供者和監管專家。這些訪談揭示了目前的驗證實踐、商業化策略以及應用障礙。

將數位生物標記創新與協作框架結合，為醫療保健轉型規劃道路

數位生物標記代表技術創新與臨床需求的融合，為改善患者照護、簡化藥物開發和轉變醫療服務模式提供了前所未有的機會。持續感知、高級分析和以患者為中心的設計的融合正在重新定義健康狀況的監測、疾病的診斷和治療的最佳化方式。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 整合人工智慧，提高數位生物標記的準確性和預測能力
  • 開發用於早期檢測神經退化性疾病的新型數位生物標記物
  • 合作與夥伴關係激增，推動數位生物標記創新
  • 開發心理健康數位生物標記物，用於客觀評估和治療反應
  • 擴大數位生物標記在遠端患者監護的應用，以改善慢性病管理
  • 擴大法規結構將加速數位生物標記技術的核准和採用
  • 實施區塊鏈技術，實現安全透明的數位生物標記數據管理
  • 精準醫療中數位生物標記的日益普及將使客製化治療計劃成為可能
  • 結合生理和行為數據的多模態生物標記的進展
  • 擴展穿戴式設備，實現健康指標的持續即時監測

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：數位生物標記市場（按組成部分）

  • 硬體
    • 植入
    • 感應器
    • 穿戴式裝置
      • 健身帶
      • 智慧型手錶
  • 軟體

第9章：數位生物標記市場（依生物標記類型）

  • 積極的
  • 被動的

第10章 數位生物標記市場：功能

  • 經常使用
  • 事件驅動
  • 定期

第 11 章：按治療領域分類的數位生物標記市場

  • 心臟病學
    • 心律不整
    • 心臟衰竭
  • 內分泌學
    • 糖尿病
    • 甲狀腺疾病
  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 乳癌
    • 攝護腺癌
  • 呼吸系統醫療設備

第 12 章：數位生物標記市場（按應用）

  • 疾病診斷
  • 藥物開發
  • 病患監測

第 13 章：數位生物標記市場（按最終用戶）

  • 學術研究機構
  • 生技公司
  • 醫院和診所
  • 製藥公司

14. 美國數位生物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲數位生物標記市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太數位生物標記市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • ActiGraph, LLC
    • Adherium Limited
    • Altoida, Inc.
    • Amgen Inc.
    • Aural Analytics, Inc. by Linus Health, Inc.
    • Biofourmis Pte. Ltd.
    • Biogen Inc.
    • Brainomix Limited
    • Eli Lilly and Company
    • Empatica Inc.
    • F. Hoffmann-La Roche Ltd.
    • Feel Therapeutics Inc.
    • GERO PTE. LTD.
    • Huma Therapeutics Limited
    • ICON PLC
    • IXICO PLC
    • Koneksa Health Inc.
    • Medable Inc.
    • Owkin, Inc.
    • Sonde Health, Inc
    • Teva Pharmaceutical Industries Ltd.
    • Verily Life Sciences, LLC
    • VivoSense, Inc
    • Chugai Pharmaceutical Co., Ltd.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-5C6F41F5AF45

The Digital Biomarkers Market was valued at USD 2.13 billion in 2024 and is projected to grow to USD 2.36 billion in 2025, with a CAGR of 10.80%, reaching USD 3.96 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.13 billion
Estimated Year [2025] USD 2.36 billion
Forecast Year [2030] USD 3.96 billion
CAGR (%) 10.80%

Navigating the Emergence of Digital Biomarkers as a Transformational Force in Personalized Healthcare and Clinical Insight Innovation

The healthcare sector is experiencing a fundamental shift as digital biomarkers redefine the landscape of patient monitoring, diagnostics, and therapeutic development. By capturing physiological and behavioral data through sophisticated sensors, wearables, and implantable devices, these novel indicators are enabling clinicians to assess health status continuously rather than episodically. The evolution from traditional biomarkers, which rely on intermittent laboratory measurements or imaging, to digital biomarkers represents a paradigm change in how diseases are detected, tracked, and treated.

In parallel, advancements in data analytics, machine learning algorithms, and cloud computing infrastructures have accelerated the ability to extract meaningful insights from high-volume, high-velocity streams of patient data. As a result, stakeholders across the healthcare continuum-from pharmaceutical companies to hospitals and research institutes-are integrating digital biomarkers into clinical trials, remote monitoring programs, and real-world evidence studies. This introduction presents the foundational concepts and underscores the transformative potential that digital biomarkers hold for enhancing patient outcomes, optimizing care pathways, and driving innovation within a more connected ecosystem.

Unveiling the Next Wave of Innovation: Technological Advances and Regulatory Breakthroughs Shaping the Future of Digital Biomarkers

The landscape of digital biomarkers is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing patient expectations. Breakthroughs in sensor miniaturization and power efficiency have expanded the range of physiological signals that can be captured outside clinical settings. Real-time data collection from wearable devices now enables continuous monitoring of vital signs, activity patterns, and sleep metrics, creating opportunities for early intervention and more adaptive treatment regimens.

At the same time, regulatory agencies have begun to recognize digital biomarkers as legitimate endpoints in clinical trials, paving the way for faster approvals and broader adoption. Harmonized guidelines are emerging that emphasize data quality, validation protocols, and patient privacy safeguards. This regulatory clarity is empowering software developers and device manufacturers to collaborate more confidently on integrated platforms, ensuring interoperability and compliance across jurisdictions.

Concurrently, patients are increasingly demanding personalized care experiences that reflect their lifestyles and preferences. The convergence of patient-centric design principles with advanced analytics is fostering the development of digital health ecosystems where individuals can actively participate in their treatment journeys. As these transformative elements converge, stakeholders must navigate the complex interplay of innovation, regulation, and user engagement to fully realize the promise of digital biomarkers.

Evaluating the Ripple Effects of 2025 US Tariff Policies on Supply Chain Resilience and Component Sourcing Strategies in Digital Biomarker Development

The implementation of new tariff measures in the United States has introduced challenges and opportunities for developers and manufacturers of digital biomarker devices and components. Imported sensors, microelectronics, and advanced materials now face increased duties, which has led to shifts in sourcing strategies and supply chain configurations. In response, companies are exploring alternate procurement channels and diversifying supplier portfolios to mitigate cost pressures.

These tariff-induced dynamics have accelerated investments in domestic manufacturing capabilities, reducing reliance on cross-border shipments and enhancing supply chain resilience. Emerging partnerships between hardware producers and contract manufacturers are focusing on localizing production hubs, incorporating lean manufacturing techniques, and optimizing component designs to minimize reliance on high-cost imports. In parallel, some stakeholders have begun redesigning device architectures to utilize semiconductors and sensor modules that are exempt from elevated duties, ensuring continued innovation while preserving cost efficiencies.

Ultimately, while the cumulative impact of tariff policy has created short-term adjustments, it has also stimulated a strategic realignment toward more agile, vertically integrated operations. Companies that can adapt swiftly to these evolving trade parameters will be better positioned to deliver next-generation digital biomarker solutions with greater responsiveness to market demands.

Dissecting the Digital Biomarker Ecosystem Through Multifaceted Component, Functionality, and Therapeutic Focus Lenses

In examining the digital biomarker ecosystem through a multidimensional lens, six primary segmentation criteria emerge, each offering nuanced insights into market dynamics and technological trajectories. Component analysis reveals a dichotomy between hardware and software, with hardware further delineated into implantables, sensors, and wearables; the latter grouping subdivides into fitness bands and smartwatches. This distinction underscores how sensor form factors influence data fidelity and user adoption, with smaller implantable devices suited for continuous physiological monitoring and consumer-grade wearables prioritizing ease of use and engagement.

Biomarker types bifurcate into active indicators, which require user engagement or specific stimuli to generate data, and passive indicators that capture signals without direct patient interaction. This differentiation shapes the design of monitoring protocols and informs validation strategies for clinical integration. Functionality segmentation highlights continuous monitoring applications that track health metrics in real time, event-driven models that trigger data capture upon detecting predefined thresholds, and periodic assessments conducted at scheduled intervals. Each modality aligns with different clinical objectives, from chronic disease management to acute event detection.

Applications extend across disease diagnostics, where digital signatures complement traditional tests; drug development programs that employ sensor-derived endpoints to assess therapeutic efficacy; and patient monitoring initiatives that facilitate remote care pathways. End users encompass academic and research institutes pioneering exploratory studies, biotechnology firms driving product innovation, hospitals and clinics integrating digital data into care delivery, and pharmaceutical companies seeking to enrich clinical trials with real-world evidence. Therapeutic areas of focus include cardiology-addressing arrhythmia and heart failure-endocrinology tackling diabetes mellitus and thyroid disorders, neurology with emphasis on Alzheimer's and Parkinson's diseases, oncology concentrating on breast and prostate cancers, and pulmonology monitoring respiratory function. Together, these layers of segmentation reveal the complexity of stakeholder needs and technological opportunities driving digital biomarker advancement.

Mapping Regional Adoption Variances Highlighting Regulatory Harmonization and Innovation Clusters Across Global Digital Biomarker Markets

Regional dynamics play a pivotal role in shaping the adoption and maturation of digital biomarkers, reflecting diverse regulatory frameworks, healthcare infrastructures, and investment landscapes. In the Americas, innovation hubs in North America lead the charge with robust partnerships between technology firms and healthcare providers, while Latin American markets explore pilot programs to extend remote monitoring capabilities across under-resourced areas. This region's emphasis on patient-centric value propositions is accelerating reimbursement dialogues and forging new care delivery models.

Across Europe, the Middle East, and Africa, regulatory convergence initiatives are fostering harmonized data governance standards, enabling cross-border clinical studies and streamlined device approvals. Western European nations are integrating digital biomarkers into national health systems, leveraging public-private collaborations to scale remote care, whereas emerging markets in the region are prioritizing low-cost sensor solutions tailored to local epidemiological profiles. In parallel, nascent digital health consortia in select Middle East and African countries are focusing on capacity building and infrastructure development.

In the Asia-Pacific, rapid digitalization, strong government support for smart healthcare initiatives, and high smartphone penetration rates are driving widespread adoption of wearable-based monitoring. Local manufacturers are optimizing production costs and customizing devices to regional biometrics, while cross-industry alliances are developing ecosystem platforms that integrate hospital networks, insurers, and technology providers. The varied pace of regulatory maturity across the region underscores the need for adaptive market entry strategies.

Profiling Leading Organizations Advancing Digital Biomarker Integration Through Strategic Alliances and Technology Convergence

Key companies are forging strategic pathways to maintain leadership and accelerate the integration of digital biomarkers into mainstream healthcare. Technology giants are expanding their device portfolios through acquisitions of specialized sensor startups and forming alliances with data analytics organizations to bolster artificial intelligence capabilities. Established medical device firms are embedding digital endpoints into legacy platforms, enhancing clinical trial data granularity and enabling remote patient engagement.

Biotechnology innovators are leveraging strategic partnerships with contract research organizations to validate digital endpoints in early-phase studies, while software vendors are investing in cloud-native architectures to ensure scalability and interoperability with electronic health record systems. Collaborative ventures between pharmaceutical companies and sensor manufacturers are focusing on co-development agreements that align therapeutic protocols with adaptive monitoring solutions. Additionally, cross-sector consortia are being established to define industry standards, promote data sharing frameworks, and advance regulatory acceptance of sensor-based outcomes.

Strategic Imperatives for Maintaining Competitive Edge Through Interoperability, Patient Engagement, and Supply Chain Resilience

Industry leaders must adopt a multi-pronged approach to capitalize on digital biomarker opportunities and navigate an increasingly complex ecosystem. Investing in interoperable platforms that adhere to emerging standards for data exchange will streamline integrations with electronic health records and analytical tools, reducing time to insight. Prioritizing rigorous validation frameworks in collaboration with regulatory bodies will ensure that digital endpoints meet clinical trial and reimbursement requirements, fostering broader acceptance.

Cultivating patient-centric design practices, including co-creation workshops with end users, will enhance device usability and long-term engagement. Leaders should also pursue partnerships across the healthcare value chain-from payors to contract research organizations-to co-develop outcome-based models that demonstrate the real-world impact of digital biomarkers. Building resilient supply chains through diversified sourcing and on-shore manufacturing capabilities will mitigate risks associated with trade policy fluctuations.

Finally, establishing robust data governance and privacy safeguards will protect patient trust and align with global regulations. By integrating these strategic imperatives, organizations can drive sustainable growth, deliver enhanced clinical insights, and unlock new value propositions in digital health.

Combining Primary Interviews, Literature Analysis, and Data Triangulation to Derive Comprehensive Digital Biomarker Insights

This analysis synthesizes insights derived from a rigorous mixed-methods research approach. Primary research included in-depth interviews with over 50 stakeholders spanning device manufacturers, software developers, healthcare providers, and regulatory experts. These conversations elucidated current validation practices, commercialization strategies, and perceived barriers to adoption.

Secondary research involved a comprehensive review of peer-reviewed journals, technical white papers, and regulatory guidance documents to ensure factual accuracy and contextual relevance. Industry databases and public filings were examined to trace recent partnerships and technology integrations, while case studies provided practical examples of digital biomarker deployment in clinical and real-world settings. All data underwent cross-validation through triangulation techniques to reinforce credibility and mitigate potential biases.

The resulting insights reflect a holistic understanding of technological trends, policy influences, and stakeholder priorities shaping the digital biomarker landscape today.

Synthesizing Digital Biomarker Innovations and Collaborative Frameworks to Chart a Course for Healthcare Transformation

Digital biomarkers represent a convergence of technological innovation and clinical necessity, unlocking unprecedented opportunities to enhance patient care, streamline drug development, and transform healthcare delivery models. The integration of continuous sensing, advanced analytics, and patient-centric design is redefining how health status is monitored, diseases are diagnosed, and therapies are optimized.

As regulatory frameworks evolve and stakeholder collaborations deepen, the potential for digital biomarkers to become standard components in clinical protocols grows ever more tangible. Organizations that embrace interoperable infrastructure, robust validation processes, and adaptive business models will be poised to lead the next wave of digital health innovation. The insights presented in this summary lay the groundwork for strategic decision-making, offering a roadmap to navigate a rapidly changing ecosystem and realize the full promise of sensor-driven healthcare transformation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of artificial intelligence to enhance digital biomarker accuracy and predictive capabilities
  • 5.2. Development of novel digital biomarkers for early detection of neurodegenerative diseases
  • 5.3. Surging collaborations and partnerships to advance digital biomarker innovation
  • 5.4. Development of digital biomarkers for mental health for objective assessment and treatment response
  • 5.5. Expanding use of digital biomarkers in remote patient monitoring to improve chronic disease management
  • 5.6. Growing regulatory frameworks accelerating approval and adoption of digital biomarker technologies
  • 5.7. Implementation of blockchain technology for secure and transparent digital biomarker data management
  • 5.8. Rising adoption of digital biomarkers in personalized medicine for tailored treatment plans
  • 5.9. Advancements in multi-modal digital biomarkers combining physiological and behavioral data
  • 5.10. Expansion of wearable devices enabling continuous real-time monitoring of health metrics

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Digital Biomarkers Market, by Component

  • 8.1. Introduction
  • 8.2. Hardware
    • 8.2.1. Implantables
    • 8.2.2. Sensors
    • 8.2.3. Wearables
      • 8.2.3.1. Fitness Bands
      • 8.2.3.2. Smartwatches
  • 8.3. Software

9. Digital Biomarkers Market, by Biomarker Type

  • 9.1. Introduction
  • 9.2. Active
  • 9.3. Passive

10. Digital Biomarkers Market, by Functionality

  • 10.1. Introduction
  • 10.2. Continuous
  • 10.3. Event-Driven
  • 10.4. Periodic

11. Digital Biomarkers Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiology
    • 11.2.1. Arrhythmia
    • 11.2.2. Heart Failure
  • 11.3. Endocrinology
    • 11.3.1. Diabetes Mellitus
    • 11.3.2. Thyroid Disorders
  • 11.4. Neurology
    • 11.4.1. Alzheimer's Disease
    • 11.4.2. Parkinson's Disease
  • 11.5. Oncology
    • 11.5.1. Breast Cancer
    • 11.5.2. Prostate Cancer
  • 11.6. Pulmonology

12. Digital Biomarkers Market, by Application

  • 12.1. Introduction
  • 12.2. Disease Diagnostics
  • 12.3. Drug Development
  • 12.4. Patient Monitoring

13. Digital Biomarkers Market, by End User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Biotechnology Firms
  • 13.4. Hospitals & Clinics
  • 13.5. Pharmaceutical Companies

14. Americas Digital Biomarkers Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Digital Biomarkers Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Digital Biomarkers Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. ActiGraph, LLC
    • 17.3.2. Adherium Limited
    • 17.3.3. Altoida, Inc.
    • 17.3.4. Amgen Inc.
    • 17.3.5. Aural Analytics, Inc. by Linus Health, Inc.
    • 17.3.6. Biofourmis Pte. Ltd.
    • 17.3.7. Biogen Inc.
    • 17.3.8. Brainomix Limited
    • 17.3.9. Eli Lilly and Company
    • 17.3.10. Empatica Inc.
    • 17.3.11. F. Hoffmann-La Roche Ltd.
    • 17.3.12. Feel Therapeutics Inc.
    • 17.3.13. GERO PTE. LTD.
    • 17.3.14. Huma Therapeutics Limited
    • 17.3.15. ICON PLC
    • 17.3.16. IXICO PLC
    • 17.3.17. Koneksa Health Inc.
    • 17.3.18. Medable Inc.
    • 17.3.19. Owkin, Inc.
    • 17.3.20. Sonde Health, Inc
    • 17.3.21. Teva Pharmaceutical Industries Ltd.
    • 17.3.22. Verily Life Sciences, LLC
    • 17.3.23. VivoSense, Inc
    • 17.3.24. Chugai Pharmaceutical Co., Ltd.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. DIGITAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. DIGITAL BIOMARKERS MARKET: RESEARCHAI
  • FIGURE 28. DIGITAL BIOMARKERS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. DIGITAL BIOMARKERS MARKET: RESEARCHCONTACTS
  • FIGURE 30. DIGITAL BIOMARKERS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. DIGITAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 321. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 322. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 323. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
  • TABLE 324. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
  • TABLE 325. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
  • TABLE 328. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
  • TABLE 329. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 330. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 331. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 333. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
  • TABLE 335. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 337. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 339. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 341. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 343. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 344. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 345. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 346. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 347. RUSS